Featured Stories
Ropes & Gray Achieves High Rankings in Mergermarket's Global M&A and Private Equity League Tables for 1H 2026
BOSTON, Massachusetts, July 11 -- Ropes and Gray, a law firm, issued the following news:
* * *
Ropes & Gray Achieves High Rankings in Mergermarket's Global M&A and Private Equity League Tables for 1H 2026
Ropes & Gray secured prominent rankings across Mergermarket's Global & Regional M&A, Private Equity, and Legal Advisors to Financial Advisors league tables for the first half of 2026. The results reinforce the firm's standing as a global leader in private equity and M&A transactions, with multiple top-five placements across key categories.
Private Equity rankings by deal count
* #3 - Global
... Show Full Article
BOSTON, Massachusetts, July 11 -- Ropes and Gray, a law firm, issued the following news:
* * *
Ropes & Gray Achieves High Rankings in Mergermarket's Global M&A and Private Equity League Tables for 1H 2026
Ropes & Gray secured prominent rankings across Mergermarket's Global & Regional M&A, Private Equity, and Legal Advisors to Financial Advisors league tables for the first half of 2026. The results reinforce the firm's standing as a global leader in private equity and M&A transactions, with multiple top-five placements across key categories.
Private Equity rankings by deal count
* #3 - GlobalExits
* #3 - US Exits
* #5 - US Buyouts
Private Equity rankings by value
* #3 - Global Exits
Legal Advisors to Financial Advisors rankings by deal count
* #3 - Global
* #3 - Americas
Legal Advisors to Financial Advisors rankings by value
* #5 - Global
* #5 - Americas
* #5 - Europe
Ropes & Gray's award-winning private equity and M&A practice is regularly ranked among the world's leading practices by Chambers, Legal 500, and others. The firm's consistent top-tier performance across multiple geographies and deal types reflects the depth and breadth of its transactional capabilities on behalf of clients worldwide.
* * *
Original text here: https://www.ropesgray.com/en/news-and-events/rankings-and-awards/2026/07/ropes-gray-achieves-high-rankings-in-mergermarkets-global-ma-and-private-equity-league-tables
[Category: BizLaw/Legal]
New York Life Releases 2025 Corporate Responsibility Report
NEW YORK, July 11 (TNSrpt) -- New York Life Insurance, a mutual life insurance company, issued the following news release:
* * *
New York Life releases 2025 Corporate Responsibility Report
Latest report highlights record value delivered to policy owners and continued investments in employees, communities and responsible business practices.
Highlights
* Record $2.78 billion dividend declared for eligible participating policy owners.
* More than $31.6 million in New York Life corporate and foundation grants.
* 323,900+ employee and agent volunteer hours in 2025.
* 257,000 employee learning
... Show Full Article
NEW YORK, July 11 (TNSrpt) -- New York Life Insurance, a mutual life insurance company, issued the following news release:
* * *
New York Life releases 2025 Corporate Responsibility Report
Latest report highlights record value delivered to policy owners and continued investments in employees, communities and responsible business practices.
Highlights
* Record $2.78 billion dividend declared for eligible participating policy owners.
* More than $31.6 million in New York Life corporate and foundation grants.
* 323,900+ employee and agent volunteer hours in 2025.
* 257,000 employee learninghours completed.
* Continued progress toward operational emissions reduction goals.
New York Life's 2025 Corporate Responsibility Report demonstrates how the company's values continue to drive meaningful impact for policy owners, employees, communities and other stakeholders.
-
New York Life, America's largest mutual life insurer,/1 recently released its 2025 Corporate Responsibility Report, highlighting how the company continues to deliver long-term value through strong financial performance, investments in its people, community impact and responsible business practices.
The report reflects a year of record performance and continued progress across the company's key corporate responsibility priorities.
Key highlights from the report include:
* A record $2.78 billion dividend declared for eligible participating policy owners.
* More than $18.1 billion in policy owner benefits and dividends paid.
* Employees completed more than 257,000 hours of learning and development.
* Our employees and agents contributed more than 323,900 volunteer hours in communities across the country.
* New York Life provided more than $31.6 million in charitable contributions.
* 100% of employees and agents enabled with AI productivity tools.
* A 23.8% reduction in operational Scope 1 and 2 greenhouse gas emissions compared with the company's 2019 baseline.
"New York Life's purpose is to be there for people when they need us most, and that commitment extends beyond the products and services we provide," said Amanda Lechenet, corporate vice president, Sustainability and Corporate Responsibility, New York Life. "Our Corporate Responsibility Report demonstrates how we create long-term value through financial strength, responsible business practices, investments in our people and meaningful engagement with the communities we serve. These efforts help ensure we remain a trusted partner for policy owners and stakeholders for generations to come."
The report also highlights the company's continued focus on employee development, responsible AI adoption, community engagement, operational sustainability and strong governance. Among the year's accomplishments were the launch of Ignite AI, expanded Continuous Improvement initiatives reaching nearly 5,000 employees, and continued investment in programs that support financial security, workforce development and community resilience.
As a mutual company, New York Life remains focused on balancing short-term performance with long-term stewardship, enabling the company to invest in innovation, strengthen customer experiences and continue delivering value to policy owners.
For more information about New York Life's Corporate Responsibility efforts, visit newyorklife.com/about and newyorklife.com/foundation.
1/ Based on revenue as reported by "Fortune 500 ranked within Industries, Insurance: Life, Health (Mutual)," Fortune magazine, 9/30/2025.
* * *
REPORT: https://www.newyorklife.com/assets/foundation/docs/pdfs/Corporate-Responsibility-Report.pdf
REPORT: https://www.newyorklife.com/assets/docs/pdfs/nyl-internet/file-types/2025-nyl-investment-report.pdf
* * *
Original text here: https://www.newyorklife.com/newsroom/2026/2025-corporate-responsibility-report
[Category: BizInsurance]
Lockheed Martin Advances Trident II D5 Modernization With $850M Award
BETHESDA, Maryland, July 11 [Category: BizAerospace] -- Lockheed Martin posted the following news release:
* * *
Lockheed Martin Advances Trident II D5 Modernization with $850M Award
Contract supports next phase of life extension program while expanding workforce to deliver critical sea-based American deterrent capabilities
TITUSVILLE, Fla. - Lockheed Martin (NYSE: LMT) has been awarded an $850 million contract modification from the U.S. Navy to continue design and development of the Trident II D5 Life Extension 2 (D5LE2) program - a critical piece of the nation's nuclear triad. The U.S. Department
... Show Full Article
BETHESDA, Maryland, July 11 [Category: BizAerospace] -- Lockheed Martin posted the following news release:
* * *
Lockheed Martin Advances Trident II D5 Modernization with $850M Award
Contract supports next phase of life extension program while expanding workforce to deliver critical sea-based American deterrent capabilities
TITUSVILLE, Fla. - Lockheed Martin (NYSE: LMT) has been awarded an $850 million contract modification from the U.S. Navy to continue design and development of the Trident II D5 Life Extension 2 (D5LE2) program - a critical piece of the nation's nuclear triad. The U.S. Departmentof War announced the award in April.
The Trident II D5 strategic weapon system remains a cornerstone of U.S. deterrence, recognized for its accuracy, reliability and operational performance. Originally developed in the 1980s and modernized through a life extension effort completed in 2017, the system is being further advanced to ensure its effectiveness into the 2040s and beyond.
"Lockheed Martin is fully committed to the mission as we move forward into this next phase," said Eric Scherff, vice president of Lockheed Martin's Fleet Ballistic Missile (FBM) Program. "This award marks another important step along the way as we continue delivering a credible and resilient deterrent for the American forces and allies."
WHY IT MATTERS
Submarine-launched ballistic missiles are the sea-based leg of the nation's nuclear triad, alongside intercontinental ballistic missiles and nuclear-capable bombers. Representing approximately 70 percent of deployed strategic deterrent capability, the sea-based leg provides unmatched survivability, persistent presence and operational flexibility.
A strong, modern deterrent remains essential to American national security and allied assurance. Through continued investment in programs like D5LE2, Lockheed Martin is advancing technologies that strengthen deterrence and support the warfighter in an evolving threat environment.
CAREERS THAT SUPPORT AMERICAN DEFENSE
To support this critical work, Lockheed Martin is expanding its workforce across multiple locations and actively recruiting engineers, technicians and other professionals who are passionate about national security and innovation. Opportunities are available for those seeking to contribute to a mission with a global impact.
Work will be performed in Colorado, Florida, Utah, Washington, Georgia and the National Capital Region.
* * *
About Lockheed Martin
Lockheed Martin is a global defense technology company driving innovation and advancing scientific discovery. Our all-domain mission solutions and 21st Century Security(R) vision accelerate the delivery of transformative technologies to ensure those we serve always stay ahead of ready. More information at www.Lockheedmartin.com.
* * *
Original text here: https://news.lockheedmartin.com/Lockheed-Martin-Advances-Trident-II-D5-Modernization-with-850M-Award
GSK's Licensor Hansoh Pharma Announces Positive Phase III Results for Ris-Rez in China Patient Population
LONDON, England, July 11 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on July 10, 2026:
* * *
GSK's licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population
* ARTEMIS-008, a phase III study conducted for China, met its primary endpoint of overall survival in advanced or relapsed small-cell lung cancer
* First positive phase III overall survival data for a B7-H3-targeted ADC in any tumour type
* GSK is advancing risvutatug rezetecan outside China across multiple tumour types, including lung cancer,
... Show Full Article
LONDON, England, July 11 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on July 10, 2026:
* * *
GSK's licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population
* ARTEMIS-008, a phase III study conducted for China, met its primary endpoint of overall survival in advanced or relapsed small-cell lung cancer
* First positive phase III overall survival data for a B7-H3-targeted ADC in any tumour type
* GSK is advancing risvutatug rezetecan outside China across multiple tumour types, including lung cancer,prostate cancer and other solid tumours
-
GSK plc (LSE/NYSE: GSK) licensor Hansoh Pharmaceutical Group Co., Ltd. today announced that ARTEMIS-008, its pivotal phase III trial evaluating risvutatug rezetecan (Ris-Rez) in patients with advanced or relapsed small-cell lung cancer (SCLC), met its primary endpoint of overall survival (OS). In the trial, conducted in patients in China, Ris-Rez demonstrated statistically significant and clinically meaningful improvements in OS compared with the standard of care, topotecan. Consistent benefit was also observed across key secondary endpoints, including progression-free survival. These data will be used by Hansoh Pharma for regulatory submission in China.
These are the first positive phase III overall survival data reported for a B7-H3-targeted antibody-drug conjugate (ADC) in any tumour type. The safety profile is consistent with prior Ris-Rez findings, and no new safety signals were identified.
GSK holds exclusive global rights to develop Ris-Rez outside mainland China, Hong Kong, Macau and Taiwan. GSK's broad clinical development programme includes studies in lung cancer, prostate cancer and other solid tumours, including the global phase III EMBOLD SCLC-301 trial in relapsed extensive-stage small-cell lung cancer (ES-SCLC) with pivotal data expected next year.
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK said: "These results are an important milestone as the first positive phase III overall survival data for a B7-H3-targeted ADC in any tumour type. Together, with other data generated to date, they further support the potential of B7-H3 as a promising target across lung cancer and other solid tumours and reinforce our continued development of Ris-Rez to improve standard of care in areas of high unmet need."
Most patients with ES-SCLC relapse after initial therapy and have limited treatment options, poor prognosis and significant treatment burden./1 B7-H3 is highly expressed in SCLC tumours/2,3 and the positive results from ARTEMIS-008 add to the growing body of evidence supporting the encouraging clinical activity and manageable safety profile of Ris-Rez in patients with ES-SCLC.
* * *
About risvutatug rezetecan
Ris-Rez is a novel investigational B7-H3-targeted ADC composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload. GSK acquired exclusive worldwide rights (excluding China's mainland, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to progress clinical development and commercialisation of Ris-Rez.
Regulatory designations received for Ris-Rez to date include orphan drug designations from the US Food and Drug Administration (FDA) and Japan's Ministry of Health, Labour and Welfare in SCLC and the European Medicines Agency (EMA) in a category of cancer that includes SCLC, called pulmonary neuroendocrine carcinoma; Priority Medicines (PRIME) Designation from the EMA for relapsed or refractory ES-SCLC; and Breakthrough Therapy Designations for relapsed or refractory ES-SCLC and relapsed or refractory osteosarcoma from the US FDA./4,5,6,7,8,9,10
* * *
GSK in oncology
Our ambition in oncology is to help increase overall quality of life, maximise survival and change the course of disease, expanding from our current focus on blood and gynaecologic cancers into lung and gastrointestinal cancers, as well as other solid tumours. This includes accelerating priority programmes such as antibody-drug conjugates targeting B7-H3 and B7-H4, and velzatinib, a highly selective KIT tyrosine kinase inhibitor.
* * *
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
* * *
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025, and GSK's Q1 Results for 2026.
* * *
References
1. G. Mountzios, et al. Tarlatamab in small-cell lung cancer after platinum-based chemotherapy. N Engl J Med, 393 (2025), pp. 349-361. DOI: 10.1056/NEJMoa2502099.
2. A.A. Getu, A. Tigabu, M. Zhou, J. Lu, 0. Fodstad, M. Tan. New frontiers in immune checkpoint B7-H3 (CD276) research and drug development. Mol. Cancer, 22 (2023), p. 43, 10.1186/s12943-023-01751-9.
3. M. Altan, V. Pelekanou, K.A. Schalper, M. Toki, P. Gaule, K. Syrigos, R.S. Herbst, D.L. Rimm. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. Clin. Cancer Res., 23 (2017), pp. 5202-5209, 10.1158/1078-0432.Ccr-16-3107.
4. GSK. GSK receives US FDA Breakthrough Therapy Designation for its B7-H3-targeted antibody-drug conjugate in relapsed or refractory extensive-stage small-cell lung cancer. Available at: https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-fda-breakthrough-therapy-designation/.
5. GSK. GSK's B7-H3-targeted antibody-drug conjugate, risvutatug rezetecan, granted Orphan Drug Designation for small-cell lung cancer in Japan. Available at: https://www.gsk.com/en-gb/media/press-releases/gsk-s-b7-h3-targeted-antibody-drug-conjugate-risvutatug-rezetecan-granted-orphan-drug-designation-for-small-cell-lung-cancer-in-japan/.
6. GSK. GSK's B7-H3-targeted antibody-drug conjugate, GSK'227, receives EMA Priority Medicines (PRIME) Designation in relapsed extensive-stage small-cell lung cancer. Available at: https://www.gsk.com/en-gb/media/press-releases/b7-h3-targeted-antibody-drug-conjugate-receives-ema-priority-medicines-designation-in-relapsed-extensive-stage-small-cell-lung-cancer/.
7. GSK. GSK's B7-H3-targeted antibody-drug conjugate, GSK'227, receives Orphan Drug Designation in the EU. Available at: https://www.gsk.com/en-gb/media/press-releases/gsk-s-b7-h3-targeted-antibody-drug-conjugate-gsk-227-receives-orphan-drug-designation-in-the-eu/.
8. GSK. GSK's B7-H3-targeted antibody-drug conjugate, GSK'227, receives EMA Priority Medicines (PRIME) Designation in relapsed extensive-stage small-cell lung cancer. Available at: https://www.gsk.com/en-gb/media/press-releases/b7-h3-targeted-antibody-drug-conjugate-receives-ema-priority-medicines-designation-in-relapsed-extensive-stage-small-cell-lung-cancer/.
9. GSK. GSK receives US FDA Breakthrough Therapy Designation for its B7-H3-targeted antibody-drug conjugate in relapsed or refractory extensive-stage small-cell lung cancer. Available at: https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-fda-breakthrough-therapy-designation/.
10. GSK. GSK's B7-H3-targeted antibody-drug conjugate, GSK'227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma. Available at: https://www.gsk.com/en-gb/media/press-releases/gsk-b7-h3-targeted-antibody-drug-conjugate-gsk227-receives-us-fda-breakthrough-therapy-designation-in-late-line-relapsed-or-refractory-osteosarcoma/.
* * *
Original text here: https://www.gsk.com/en-gb/media/press-releases/gsk-s-licensor-hansoh-pharma-announces-positive-phase-iii-results-for-ris-rez-in-china-patient-population/
[Category: BizPharmaceuticals]
Duke Energy Florida Delivers $50 Million in Customer Savings, Avoids 2027 Base Rate Increase Through Innovative Tax Strategy
CHARLOTTE, North Carolina, July 11 -- Duke Energy issued the following news release:
* * *
Duke Energy Florida delivers $50 million in customer savings, avoids 2027 base rate increase through innovative tax strategy
Duke Energy Florida is delivering $50 million in customer savings in 2027. The company is implementing an innovative strategy to accelerate the return of tax credits over one year rather than the standard 15-year lifespan of its Powerline Battery Energy Storage System. This will avoid the 2% base rate increase outlined in its multiyear (2025-2027) rate agreement and help keep costs
... Show Full Article
CHARLOTTE, North Carolina, July 11 -- Duke Energy issued the following news release:
* * *
Duke Energy Florida delivers $50 million in customer savings, avoids 2027 base rate increase through innovative tax strategy
Duke Energy Florida is delivering $50 million in customer savings in 2027. The company is implementing an innovative strategy to accelerate the return of tax credits over one year rather than the standard 15-year lifespan of its Powerline Battery Energy Storage System. This will avoid the 2% base rate increase outlined in its multiyear (2025-2027) rate agreement and help keep costsas low as possible for customers.
Our view
"Our customers count on us to continually look for ways to keep our costs in check and help ease their overall financial burden - especially as prices continue to rise in seemingly every aspect of our daily lives," said Melissa Seixas, Duke Energy Florida state president. "By finding a way to return these tax credits faster, we're able to put millions of dollars to work for our customers sooner, while also building the modern energy infrastructure Florida's rapidly growing communities need."
Better reliability, more savings
* Over the next 10 years, Duke Energy Florida plans to build 1.4 gigawatts of battery storage, which will result in more than $500 million in investment tax credits that the company will pass on directly to customers.
* Batteries play an important role in Duke Energy Florida's "all-of-the-above" approach to power generation, storing electricity when demand is low and making it available when customers need it most.
- The company currently has six sites located throughout the state; the Powerline Battery Energy Storage System in Citrus County will be the seventh site when it is completed next year.
* The more batteries Duke Energy Florida adds to its portfolio, the more useful solar energy sites become, as customers can benefit from the stored energy even when it is cloudy or the sun has gone down.
- The company is working to establish 12 new solar energy sites by the end of 2028, saving customers a total of approximately $3 billion in displaced fuel costs throughout their service lifetimes.
- In 2025, the company passed on approximately $65 million in production tax credits from solar energy sites to customers - an amount that will grow as more sites are completed - reducing residential rates by at least $2.50 per 1,000 kilowatt-hours of electricity used.
Need help now?
While Duke Energy Florida lowered residential customers' rates three times in 2026 and continues to look for new, creative ways to provide relief, the company understands energy use - and bills - may be surging as temperatures rise this summer. Customers are encouraged to take advantage of the many energy efficiency and financial assistance programs available to them, from free assessments of their home's energy use to flexible payment plans. For more information, please visit duke-energy.com/SummerSolutions.
* * *
Duke Energy Florida
Duke Energy Florida, a subsidiary of Duke Energy, owns 12,500 megawatts of energy capacity, supplying electricity to 2 million residential, commercial and industrial customers across a 13,000-square-mile service area in Florida.
* * *
Duke Energy
Duke Energy (NYSE: DUK), a Fortune 150 company headquartered in Charlotte, N.C., is one of America's largest energy holding companies. The company's electric utilities serve 8.7 million customers in North Carolina, South Carolina, Florida, Indiana, Ohio and Kentucky, and collectively own 55,700 megawatts of energy capacity. Its natural gas utilities serve 1.6 million customers in North Carolina, South Carolina, Ohio and Kentucky.
Duke Energy is executing an energy modernization strategy, keeping customer value at the forefront as it invests in electric grid upgrades and efficient generation resources to strengthen the system and serve growing energy needs.
* * *
Original text here: https://news.duke-energy.com/releases/duke-energy-florida-delivers-50-million-in-customer-savings-avoids-2027-base-rate-increase-through-innovative-tax-strategy
[Category: BizEnergy]
Aircraft Lessor Azorra Completes 52 Transactions in Strong Q2 2026
FORT LAUDERDALE, Florida, July 11 -- Azorra, an aircraft lessor that says it provides financing, fleet transition and asset management solutions to investors, financiers and airline operators, issued the following news release:
* * *
Azorra Second Quarter 2026 activity
Azorra announces its second quarter activity as it completed 52 transactions, underscoring continued momentum of its leasing, trading, and portfolio management capabilities.
* Signed and extended leases: 9 aircraft and 5 engines
* Purchased: 8 aircraft, 7 engines and 1 airframe
* Delivered: 8 aircraft and 7 engines
* Sold:
... Show Full Article
FORT LAUDERDALE, Florida, July 11 -- Azorra, an aircraft lessor that says it provides financing, fleet transition and asset management solutions to investors, financiers and airline operators, issued the following news release:
* * *
Azorra Second Quarter 2026 activity
Azorra announces its second quarter activity as it completed 52 transactions, underscoring continued momentum of its leasing, trading, and portfolio management capabilities.
* Signed and extended leases: 9 aircraft and 5 engines
* Purchased: 8 aircraft, 7 engines and 1 airframe
* Delivered: 8 aircraft and 7 engines
* Sold:5 aircraft and 2 airframes
* Orderbook commitments: 21 additional aircraft
During the second quarter Azorra completed the portfolio acquisitions of 12 Airbus A220-300s from EGYPTAIR, 49 Embraer E-Jets and 2 CF34-10E engines from Dubai Aerospace Enterprise ("DAE"), and 13 Embraer E190 airframes and 36 CF34-10E engines from JetBlue.
Azorra also increased its commitments through the purchase of the eight A220-300 orderbook from DAE (two of which have delivered to TAAG Angola) and the exercise of 15 additional Embraer E195-E2s orders further strengthening its next-generation aircraft portfolio and reinforcing its commitment to meeting growing customer demand worldwide.
As of June 30, 2026, Azorra's portfolio statistics are as follows:
* Total Current and committed fleet: 224 aircraft, 86 engines, and 13 airframes
* Owned and managed: 187 aircraft, 86 engines, and 13 airframes
* Commitments: 37 aircraft
* Customer diversification: 43 customers in 37 countries
* * *
ABOUT AZORRA
Azorra is a relationship-driven aircraft lessor that provides leasing, financing, fleet transition and asset management solutions to aircraft investors, financiers and airline operators worldwide. Azorra's multi-cultural team reflects the global markets that the company serves and includes core competencies in aviation law, aircraft finance, maintenance, marketing, sales, trading and leasing.
The team is led by seasoned veterans having a shared history of success and is complemented by young professionals who bring fresh perspective, ideas and enthusiasm. Azorra's current fleet comprises 323 aviation assets, including 187 owned and managed aircraft, 99 owned engines and airframes, and a commitment pipeline of 37 aircraft. These commitments include orders for new Airbus A220-100/300 aircraft and Embraer E190/E195-E2 aircraft. Azorra is headquartered in Fort Lauderdale, Florida, with an office in Dublin, Ireland.
* * *
Original text here: https://azorra.com/2026/07/09/azorra-second-quarter-2026-activity/
[Category: BizAerospace]
19 Years and Counting ... American Family Life Insurance Company Recognized Again With Ward's Top 50 Designation
MADISON, Wisconsin, July 11 -- American Family Insurance issued the following news release:
* * *
19 years and counting ... American Family Life Insurance Company recognized again with Ward's Top 50 designation
American Family Life Insurance Company's ongoing commitment to excellence has landed them a place on Ward's Top 50 for another year.
-
American Family Life Insurance Company (AFLIC) has been named to the Ward's Top 50 list, as one of the nation's top 50 performing life/health insurance companies, for the 19th consecutive year.
AFLIC is one of only seven life/health companies to be
... Show Full Article
MADISON, Wisconsin, July 11 -- American Family Insurance issued the following news release:
* * *
19 years and counting ... American Family Life Insurance Company recognized again with Ward's Top 50 designation
American Family Life Insurance Company's ongoing commitment to excellence has landed them a place on Ward's Top 50 for another year.
-
American Family Life Insurance Company (AFLIC) has been named to the Ward's Top 50 list, as one of the nation's top 50 performing life/health insurance companies, for the 19th consecutive year.
AFLIC is one of only seven life/health companies to benamed to the Ward's Top 50 list for 19 consecutive years.
Ward Group is a consulting firm that helps insurance companies optimize performance and improve profitability by providing operational and compensation benchmarking and best practices.
Each year, Ward Group analyzes the financial performance of nearly 700 life/health insurance companies domiciled in the United States and identifies the top performers. Each Ward's 50 company, including AFLIC, has achieved outstanding financial results in the areas of safety, consistency and performance over a five-year period.
To earn the Ward's 50 designation and be recognized as a top performer, insurance companies must demonstrate financial stability and meet specific performance criteria. These include maintaining a robust capital position, achieving revenue growth and delivering strong underwriting results. Companies are also evaluated based on their ability to surpass minimum thresholds in areas such as capital/surplus, net income and financial returns.
"Our customers depend on us for the peace of mind life insurance brings and to trust we'll be there for them when we're needed most," said Todd Fancher, American Family Life Insurance Company president. "The commitment to quality, performance and financial stability our life organization demonstrates every day has been recognized by Ward's for the 19th year in a row and reaffirms that deep commitment we make to our customers."
* * *
About American Family Insurance
American Family Insurance based in Madison, Wis., has been serving customers since 1927. We inspire, protect and restore dreams through our insurance products, exceptional service from our agency owners and employees, community investments and creative partnerships. American Family Insurance is the nation's 12th-largest property/casualty insurance company, ranking No. 226 on the Fortune 500 list. American Family has a current 'a+' credit rating through AM Best, and has distinction as a "Standing the Test of Time" company, which is represented by having an AM Best financial strength rating of 'A' or better for at least 75 years. The company offers American Family-brand products through a network of exclusive agency owners as well as nationwide through key strategic partnerships. American Family Insurance also includes Homesite and Main Street America Insurance. The company has approximately 10,500 employees nationwide[JM1] .
Life insurance underwritten by American Family Life Insurance Company, 6000 American Parkway, Madison, WI 53783. American Family Life Insurance Company has an AM Best financial strength rating of 'A' (Excellent), the third highest of their 13 ratings; and an 'a+' (Excellent) long-term issuer credit rating, the fifth highest of their 21 ratings.
* * *
Original text here: https://newsroom.amfam.com/19-years-and-counting--american-family-life-insurance-company-recognized-again-with-wards-top-50-designation/
[Category: BizInsurance]
